Project Grant R01HL175410
Award Date
7/1/24
Completion Date
4/30/28
Dollars Obligated
$3.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44106, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to New York University School of Medicine, totaling $198,936.00 with a start date of August 5, 2024 and an ultimate completion date of July 31, 2029. The grant will fund research to quantify the effects of restrictive drug coverage policies for guideline-recommended heart failure medications on provider prescribing, patient adherence, and clinical...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $651,840 to the University of Toledo Health Science Campus Division to develop a Kidney Tubule Health Panel (KTHP) that can better monitor kidney health during treatment for resistant hypertension. The goal is to create a urine-based biomarker panel that can distinguish between acute kidney injury and benign changes in creatinine levels...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), will provide $671,986 to strengthen the evidence base for medication prescribing in older adults with chronic kidney disease (CKD). The key objectives are to evaluate the effectiveness of renoprotective therapies, such as angiotensin converting enzyme inhibitors (ACEIs) and...
This federal Project Grant award of $703,523, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop an innovative microrobotic drug delivery system to prevent vascular complications in end-stage kidney disease (ESKD) patients. The project will refine the microrobotic technology for safe and effective endoluminal drug delivery, identify the maximum deliverable non-toxic dose of the drug AZD8797, and...
This $708,678 Project Grant was awarded on March 4, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant will fund a Sequential Multiple Assignment Randomized Trial (SMART) to evaluate interventions aimed at reducing food insecurity and improving adherence to hypertension treatments among patients with uncontrolled hypertension. The study, conducted in partnership with Wake Forest University Health Sciences,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,321,108 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to New York University School of Medicine to conduct transdisciplinary implementation research on a strategy called PT4A. PT4A integrates peer-based medication delivery, peer coaching, and health information technology to improve medication adherence and reduce blood pressure among patients with uncontrolled hypertension in Western Kenya. The study aims to...
This $1,092,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the Medical College of Wisconsin, Inc. (MCW) to elucidate the molecular and physiological mechanisms controlling vascular function, arterial stiffness, and blood pressure regulation at the intersection of the renin-angiotensin system and the PPARG-RHOBTB1-CULLIN-3 pathways. The 7-year research program aims to...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $312,198 to the University of California, San Francisco (UCSF) to elucidate patterns of cardiovascular disease risk in adolescent and young adult patients with kidney disease. The key objectives are to understand barriers to implementation of cardiovascular risk reduction therapies and test the acceptability and clinical utility of...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $299,604 Project Grant (R01HL177813) to Case Western Reserve University (CWRU) to develop and validate a novel "Transfer Volume Regression" method to enable quantitative clinical risk predictions for major cardiovascular events, including stroke, heart attack, heart failure, and death. The 4-year project aims to create a smart, standardized,...
The federal Project Grant award K24HL177273, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $137,219 to the University of Illinois at Chicago from December 2024 through November 2029. The award supports the development of the awardee, Dr. Santosh L. Saraf, as a mentor to the next generation of clinician scientists focused on sickle cell disease (SCD)-related research, particularly in the area of...